This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), (
http://www.apricusbio.com ) today announced that Linda Smibert, Vice President, Business Development at the Company's NexMed, USA, Inc. ("NexMed, USA") subsidiary, will present at the BioPartnering North America Conference
™ in Vancouver, Canada, on Tuesday, March 1, 2011, at 10:15 am PST. The presentation will include an overview of the Company's commercialization plans for Vitaros
®, its first approved product, as well as development of the Company's 12 other products and compounds utilizing its proprietary NexACT
On November 12, 2010, Apricus Bio announced that Health Canada had approved Vitaros
® for marketing as the first topical treatment for ED in that country. The Company announced on December 22, 2010 a licensing agreement with Bracco SpA for the commercialization of Vitaros
® in Italy, and on January 4, 2011, announced the signing of a licensing agreement with Elis Pharmaceuticals for the Gulf Countries and certain countries in the Middle East. Apricus Bio is currently in proactive discussions to expand the commercialization of Vitaros
® to certain other international markets.
Commenting on the upcoming presentation, Dr. Bassam Damaj, President and Chief Executive Officer of the Company, noted, "We are very excited to have this opportunity to present a review of our commercialization progress for Vitaros
® at such a key industry event. Our business development group at NexMed USA has been very proactive in seeking appropriate licensing and commercialization partners throughout the world in order to potentially make this promising drug available to patients in many different countries. In addition to this review, Ms. Smibert will be presenting an update on our 12 other products and compounds in development, including later stage products, such as MycoVa
™ for onychomycosis (nail fungus), PrevOnco
™ for liver cancer, Femprox
® for female sexual arousal disorder, and RayVa
™ for Raynauld's Syndrome, as well as our pre-clinical products in development, in the areas of sexual dysfunction, oncology, autoimmune disease, anti-inflammatory, pain, anti-infectives, diabetes and cosmeceuticals. We are enthusiastic about the opportunity to discuss these products, as well as the underlying NexACT
® technology, and how it may help other companies achieve better results from their own compounds and products."
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT
® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide, as well as monetizing its existing product pipeline, including its approved drug, Vitaros
®, for treatment of erectile dysfunction, in addition to compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals, among others. For further information on Apricus Bio and its subsidiaries, visit
http://www.apricusbio.comApricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, timing for seeking foreign approvals for Vitaros
®, timing and success of the commercial launch of Vitaros
® in Italy, The Gulf Countries and part of the Middle East and in Israel and the Palestinian Territories, the potential size of the markets in each of these countries, the ability to develop and commercialize the Company's products on its own and with partners and the ability to meet its milestones. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc.
VP, Investor Relations & Corporate Development
Apricus Bio Investor Relations
Rx Communications Group, LLC